Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $90,200.00 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CFO Avraham Gabay sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the sale, the chief financial officer directly owned 861,076 shares in the company, valued at $3,883,452.76. The trade was a 2.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $4.49 on Monday. The firm has a market cap of $186.78 million, a price-to-earnings ratio of 1.09 and a beta of 1.29. The company has a 50 day moving average price of $4.64 and a 200-day moving average price of $4.20. Oramed Pharmaceuticals Inc. has a 1-year low of $2.09 and a 1-year high of $5.47.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). On average, sell-side analysts anticipate that Oramed Pharmaceuticals Inc. will post 1.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP purchased a new stake in Oramed Pharmaceuticals during the 2nd quarter worth approximately $61,000. Bank of New York Mellon Corp acquired a new stake in shares of Oramed Pharmaceuticals in the second quarter worth approximately $381,000. Bank of America Corp DE boosted its stake in shares of Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 3,909 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Oramed Pharmaceuticals during the first quarter worth approximately $63,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 7,738 shares in the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on ORMP shares. Wall Street Zen upgraded Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Oramed Pharmaceuticals in a research report on Tuesday, September 8th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream.

The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies.